Gilead Sciences logo

Gilead SciencesNASDAQ: GILD

Profile

Sector:

Healthcare

Country:

United States

IPO:

22 January 1992

Next earnings report:

06 November 2024

Last dividends:

13 September 2024

Next dividends:

N/A
$110.78 B
-1%vs. 3y high
99%vs. sector
108.51
-46%vs. 3y high
90%vs. sector
0%vs. 3y high
85%vs. sector
-3%vs. 3y high
54%vs. sector

Price

regular market | 8 min ago
$88.98+$0.81(+0.92%)
$6.95 B$7.00 B
$6.95 B$1.61 B

Analysts recommendations

Institutional Ownership

GILD Latest News

Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
zacks.com01 November 2024 Sentiment: -

Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
zacks.com29 October 2024 Sentiment: NEUTRAL

Gilead Sciences (GILD) closed at $88.08 on the most recent trading day, showing a decrease of 0.77% from its previous closing price.

3 Absurdly Cheap Stocks That Pay High Dividends
fool.com24 October 2024 Sentiment: POSITIVE

These stocks are being sold for under 15 times what they are predicted to earn in the future.

Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
zacks.com23 October 2024 Sentiment: NEUTRAL

At the end of the last trading day, Gilead Sciences (GILD) was priced at $87.23, which represents a decrease of 1.05% compared to the day before.

Gilead voluntarily withdraws urothelial cancer drug in US
reuters.com18 October 2024 Sentiment: NEGATIVE

On Friday, Gilead Sciences announced that it is choosing to withdraw the U.S. approval for Trodelvy, which is used for patients with a specific type of urothelial cancer who have already received treatment. This decision was made after discussions with the regulatory authorities.

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
benzinga.com17 October 2024 Sentiment: POSITIVE

Leading analysts on Wall Street have updated their opinions on these major companies. To see all the changes in analyst ratings, including both upgrades and downgrades, visit our analyst ratings page.

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
zacks.com15 October 2024 Sentiment: POSITIVE

Gilead Sciences (GILD) closed at $85.83 on the most recent trading day, showing an increase of 0.91% from its previous closing price.

Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
zacks.com11 October 2024 Sentiment: POSITIVE

GILD's latest positive results on lenacapavir highlight the drug's possible effectiveness in preventing HIV among the specific group of people.

Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know
zacks.com08 October 2024 Sentiment: POSITIVE

Gilead Sciences (GILD) closed at $85.21 on the most recent trading day, showing an increase of 0.92% from its previous closing price.

Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation
seekingalpha.com05 October 2024 Sentiment: POSITIVE

Gilead's lenacapavir could become a major HIV prevention drug. Biktarvy continues to hold a large share of the HIV treatment market, which helps boost Gilead's earnings. Additionally, Gilead's cancer treatment division is growing, with Trodelvy and Yescarta showing promise for increased sales.

What type of business is Gilead Sciences?

Gilead Sciences, Inc. is an American research-based biopharmaceutical company founded in 1987 with headquarters in Foster City, California. The company is engaged in the search, development, and commercialization of innovative drugs for serious diseases such as HIV, AIDS, liver disease, hematology, oncology, and respiratory diseases. The company produces a wide range of products under its own brands, including AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Epclusa, Genvoya, Harvoni, Hepsera, Letairis, Odefsey, Ranexa, Sovaldi, Stribild, Tybost, Vemlidy, Vosevi, Yescarta, Zydelig, and others. The existing product portfolio is constantly being supplemented and expanded through the company's ongoing research and development, licensing, and strategic partnerships.

What sector is Gilead Sciences in?

Gilead Sciences is in the Healthcare sector

What industry is Gilead Sciences in?

Gilead Sciences is in the Drug Manufacturers - General industry

What country is Gilead Sciences from?

Gilead Sciences is headquartered in United States

When did Gilead Sciences go public?

Gilead Sciences initial public offering (IPO) was on 22 January 1992

What is Gilead Sciences website?

https://www.gilead.com

Is Gilead Sciences in the S&P 500?

Yes, Gilead Sciences is included in the S&P 500 index

Is Gilead Sciences in the NASDAQ 100?

Yes, Gilead Sciences is included in the NASDAQ 100 index

Is Gilead Sciences in the Dow Jones?

No, Gilead Sciences is not included in the Dow Jones index

When was Gilead Sciences the previous earnings report?

No data

When does Gilead Sciences earnings report?

The next expected earnings date for Gilead Sciences is 06 November 2024